Xencor, Inc. - Common Stock (NQ:XNCR)

25.35 +0.51 (+2.05%)

Delayed Quote Updated: 10:02 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Xencor, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

7 Battered Stocks That Could TRIPLE by 2024 ↗

July 03, 2023

While heavily deflated enterprises are usually that way for a reason, speculators may gamble on these battered stocks to buy.

Via InvestorPlace

Xencor Presents Clinical Results from Phase 1a Study of XmAb®564 at the EULAR 2023 Congress

May 30, 2023

From Xencor, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For May 19, 2023 ↗

May 19, 2023

Via Benzinga

What 6 Analyst Ratings Have To Say About Xencor ↗

May 09, 2023

Via Benzinga

Earnings Outlook For Xencor ↗

May 05, 2023

Via Benzinga

Why Shares of Zencor Rose This Week ↗

January 26, 2023

The clinical-stage biotech has seen its shares rise since a company presentation a few weeks ago.

Via The Motley Fool

Xencor Reports First Quarter 2023 Financial Results

May 08, 2023

From Xencor, Inc.

Via Business Wire

Earnings Scheduled For May 8, 2023 ↗

May 08, 2023

Companies Reporting Before The Bell • HNI (NYSE:HNI) is likely to report quarterly loss at $0.03 per share on revenue of $462.26 million.

Via Benzinga

Xencor to Host First Quarter 2023 Financial Results Webcast and Conference Call on May 8, 2023

May 01, 2023

From Xencor, Inc.

Via Business Wire

Xencor's Return On Capital Employed Overview ↗

December 01, 2022

Via Benzinga

Xencor Appoints Nancy Valente, M.D., as Chief Development Officer

April 26, 2023

From Xencor, Inc.

Via Business Wire

Xencor Highlights CD28 Bispecific Antibody Platform at AACR Annual Meeting 2023

April 17, 2023

From Xencor, Inc.

Via Business Wire

7 Biotech Stocks to Buy for 100% Returns ↗

April 09, 2023

If you can handle the risks associated with high volatility, these biotech stocks to buy might double the returns in your portfolio.

Via InvestorPlace

Xencor to Present Preclinical Data from Novel XmAb® CD28 Bispecific Antibody Programs at the American Association for Cancer Research Annual Meeting 2023

March 14, 2023

From Xencor, Inc.

Via Business Wire

Xencor Reports Fourth Quarter and Full Year 2022 Financial Results

February 23, 2023

From Xencor, Inc.

Via Business Wire

Xencor to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 23, 2023

February 16, 2023

From Xencor, Inc.

Via Business Wire

Top 5 Health Care Stocks That May Collapse In February ↗

February 13, 2023

The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.

Via Benzinga

Xencor to Present at the SVB Securities Global Biopharma Conference

February 07, 2023

From Xencor, Inc.

Via Business Wire

Earnings Scheduled For February 23, 2023 ↗

February 23, 2023

Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2023 ↗

January 31, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For January 30, 2023 ↗

January 30, 2023

Via Benzinga

3 Small-Cap Biopharma Stocks that Could See Big Growth in 2023

January 13, 2023

Health care stocks are trying to make a comeback and these three small-cap biopharma companies are leading the charge in some ways.

Via MarketBeat

Xencor Highlights 2023 Corporate Priorities and Provides Portfolio Updates

January 09, 2023

From Xencor, Inc.

Via Business Wire

Xencor to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 04, 2023

From Xencor, Inc.

Via Business Wire

Xencor Presents Data from Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin Lymphoma at the American Society of Hematology Annual Meeting

December 12, 2022

From Xencor, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For December 6, 2022 ↗

December 06, 2022

Via Benzinga

Xencor to Present at Upcoming Investor Conferences

November 10, 2022

From Xencor, Inc.

Via Business Wire

Xencor Presents Early Clinical Data from Combination Study of Vudalimab and New Data from Multiple Preclinical-stage XmAb® Programs at the SITC Annual Meeting

November 10, 2022

From Xencor, Inc.

Via Business Wire

Xencor Reports Third Quarter 2022 Financial Results

November 07, 2022

From Xencor, Inc.

Via Business Wire

Xencor’s IL2-Fc Cytokine, XmAb®564, is Well-tolerated and Selectively Expands Regulatory T Cells in Phase 1a Clinical Study

November 07, 2022

From Xencor, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.